Who
Jean I. Liu
Director
Company insider
Files Form 4 as: Director, Connect Biopharma Holdings; Director, Erasca; Chief Legal Officer, Seagen; VP & General Counsel, Halozyme Therapeutics; Chief Legal Officer, Durect.
In numbers
- Trades disclosed
- 197
- Buys
- 0
- Sells
- 32
- Bought
- $0
- Sold
- $22.9M
- Companies
- 5
- Companies where not an officer
- 2
- First trade
- 6 Jan 2006
- Last trade
- 30 Sep 2026
- Last filed
- 1 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 30 Sep 2026filed 1 Oct 2026 | CNTB Connect Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —8,984 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | CNTB Connect Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —6,718 at $0.00 | filing |
| 30 Jun 2026filed 1 Jul 2026 | CNTB Connect Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —6,718 at $0.00 | filing |
| 26 Jun 2026filed 29 Jun 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,888 at $0.00 | filing |
| 26 Jun 2026filed 29 Jun 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,888 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | CNTB Connect Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —5,061 at $0.00 | filing |
| 31 Mar 2026filed 2 Apr 2026 | CNTB Connect Biopharma HoldingsBiotechnology | SEC FORM 4 Code A | —5,061 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,617 at $0.00 | filing |
| 1 Jan 2026filed 5 Jan 2026 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,617 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —120,000 at $0.00 | filing |
| 1 Jan 2025filed 2 Jan 2025 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,939 at $0.00 | filing |
| 20 Jun 2024filed 21 Jun 2024 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 1 Jan 2024filed 3 Jan 2024 | ERAS Erascaoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,482 at $0.00 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —7,446 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —35,293 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —40,344 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —40,523 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —1,333 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —43,786 | filing |
| 14 Dec 2023filed 15 Dec 2023 | Seagenoption or derivative | SEC FORM 4 Code D | —636 | filing |
News
No headline names them, or the companies they trade most, lately.